With SITC fast coming up this week, immunotherapies in all sorts of shapes and guises are very much going to be at the forefront of many people’s attention.

The Fall conference season is in full swing – time to take a look at an emerging new development

Aside from various well established approaches though, is there anything new on the horizon?

It turns out there is something that caught our imagination at BSB.

The good news it’s not yet another X checkpoint inhibitor/immune agonist/cytokine – this concept is both a novel and a compelling one.

It also potentially fills a need not addressed by the other approaches.

Want to learn more about this intriguing approach based on rationally driven science?

BSB subscribers can read up on our ongoing commentary and analysis from the cancer conference season – you can either log-in or click to access our latest analysis.

This content is restricted to subscribers

Posted by